Corbus Pharmaceuticals Holdings, Inc.
CRBP
$8.88
-$0.18-1.93%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -11.76% | 37.35% | |||
| Gross Profit | 11.76% | -37.35% | |||
| SG&A Expenses | 0.08% | -10.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.04% | 27.49% | |||
| Operating Income | 10.04% | -27.49% | |||
| Income Before Tax | 11.94% | -32.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.94% | -32.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.94% | -32.16% | |||
| EBIT | 10.04% | -27.49% | |||
| EBITDA | 10.05% | -27.58% | |||
| EPS Basic | 34.39% | -31.44% | |||
| Normalized Basic EPS | 30.88% | -31.45% | |||
| EPS Diluted | 34.39% | -31.44% | |||
| Normalized Diluted EPS | 30.88% | -31.45% | |||
| Average Basic Shares Outstanding | 34.21% | 0.55% | |||
| Average Diluted Shares Outstanding | 34.21% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||